ライフサイエンスコーパス: TMP-SMX

1 TMP-SMX administration significantly reduced liver stage

2 TMP-SMX and LVX had high minor errors, CAZ had unaccepta

3 TMP-SMX appears to be as effective and safer than pyrime

4 TMP-SMX ARDS is a diagnosis of exclusion.

5 TMP-SMX inhibited development of rodent and P. falciparu

6 TMP-SMX is a commonly prescribed antibiotic.

7 TMP-SMX is not gametocytocidal, but at prophylactic leve

8 TMP-SMX was associated with increased risk of severe car

9 cohort included 248 236 individuals (51 197 TMP-SMX users and 197 039 cephalosporin users; median ag

10 olones (35%), followed by carbapenems (20%), TMP-SMX (18.5%), and ceftazidime (11%).

11 class 1 integron was found in 25 (93%) of 27 TMP-SMX-resistant CgA isolates but in only 43 (63%) of 6

12 n-CgA isolates (P < 0.001) and in none of 44 TMP-SMX-susceptible E. coli isolates (P < 0.0001).

13 tant CgA isolates but in only 43 (63%) of 68 TMP-SMX-resistant non-CgA isolates (P < 0.001) and in no

14 cohort included 575 218 individuals (44 801 TMP-SMX users and 530 417 amoxicillin users; median age

15 (59.2%) nitrofurantoin-exposed, 3494 (4.9%) TMP-SMX-exposed, 3663 (5.1%) fluoroquinolone-exposed, an

16 ) clindamycin-treated and 182 of 198 (91.9%) TMP-SMX-treated subjects (difference, 0.2%; 95% confiden

17 Among 95 TMP-SMX-resistant isolates, 68 and 27 isolates carried c

18 e was 39% against ciprofloxacin, 44% against TMP-SMX, and 25% against cefuroxime.

19 solate, and 5% were resistant to ampicillin, TMP-SMX, and chloramphenicol.

20 line (n = 2351), sulfadiazine (n = 870), and TMP-SMX (n = 23 602).

21 The TMP-SMX vs amoxicillin and TMP-SMX vs cephalosporins cohorts both included adolesce

22 neumoniae ) sensitivity to ciprofloxacin and TMP-SMX was calculated using 2021 Veterans Health Admini

23 ngs where MRSA is prevalent, clindamycin and TMP-SMX produce similar cure and adverse event rates amo

24 gnificant difference between clindamycin and TMP-SMX, with respect to either efficacy or side-effect

25 tandard therapy for systemic listerosis, and TMP-SMX may be used for patients with beta-lactam intole

26 9%, 98%, and 96% for CAZ, LVX, MEM, MIN, and TMP-SMX, respectively.

27 f in vitro susceptibility to minocycline and TMP-SMX.

28 We characterized NNRTI and TMP-SMX effects on Plasmodium liver stages in vivo using

29 -effects and poor adherence by patients, and TMP-SMX alone is recommended in Australia.

30 cant increase in tetracycline resistance and TMP-SMX resistance, modest and not significant increases

31 grams/ml for resistance for both species and TMP-SMX MIC breakpoints of < or = 2.0-38 micrograms/ml f

32 Prenatal exposure to streptomycin and TMP-SMX was associated with select birth defects in some

33 her rates of resistance to tetracyclines and TMP-SMX, particularly among MRSA isolates.

34 ates of resistance to both tetracyclines and TMP-SMX.

35 increasingly resistant to tetracyclines and TMP-SMX.

36 rd trends in clindamycin, tetracyclines, and TMP-SMX resistance were observed.

37 ase inhibitor nevirapine, and the antibiotic TMP-SMX were assessed for activity against Plasmodium fa

38 lts, we conducted in vitro studies assessing TMP-SMX effects on the rodent parasites P. yoelii and Pl

39 : One hundred percent of currently available TMP-SMX respiratory failure patient genomic data, ( n =

40 ity were not significantly different between TMP-SMX and pyrimethamine-containing regimens (P > .05).

41 were sequenced, and the relationship between TMP-SMX or dapsone use and gene mutations was analyzed.

42 These findings support modern RCTs comparing TMP-SMX to pyrimethamine-based therapies and a revisitin

43 ere 1.0 to 4.0 micrograms/ml and the current TMP-SMX MIC range was confirmed.

44 ed, placebo-controlled trial comparing daily TMP-SMX plus monthly dihydroartemisinin-piperaquine (DP)

45 the daily TMP-SMX plus DP arm and the daily TMP-SMX alone arm (6.1% vs. 3.1%; relative risk, 1.96; 9

46 acental malarial infection between the daily TMP-SMX plus DP arm and the daily TMP-SMX alone arm (6.1

47 dihydroartemisinin-piperaquine (DP) to daily TMP-SMX alone in HIV-infected pregnant women in an area

48 g of insecticide, adding monthly DP to daily TMP-SMX did not reduce the risk of placental or maternal

49 antibiotic (nitrofurantoin, 62 [45-77] days; TMP-SMX, 26 [13-59] days; fluoroquinolones, 18 [9-27] da

50 with hematologic malignancies, reduced-dose TMP-SMX was effective and safe for treating mild to mode

51 peated exposures to malaria parasites during TMP-SMX administration induces stage-specific and long-l

52 Emerging CC1292 expressed TMP-SMX resistance and decreased susceptibility to penic

53 of weighted events, 7 of 21 579 [0.03%] for TMP-SMX and 2 of 21 579 [0.01%] for amoxicillin; weighte

54 of weighted events, 8 of 20 538 [0.04%] for TMP-SMX and 3 of 20 538 [0.01%] for cephalosporins; weig

55 in sensitivity was 76%-100% and 72%-100% for TMP-SMX.

56 nsitivity rates were 50%-87% and 43%-92% for TMP-SMX.

57 integrons harboring resistance cassettes for TMP-SMX (dfr) was examined.

58 atient setting, identifying risk factors for TMP-SMX resistance and knowing the prevalence of TMP-SMX

59 f any congenital malformation was higher for TMP-SMX (RR, 1.35; 95% CI, 1.04-1.75) but similar for ni

60 6.9 (95% CI, 21.8-32.8) per 1000 infants for TMP-SMX.

61 The current limits for TMP-SMX were confirmed.

62 p <0.0001); those taking TMP-SMX had higher TMP-SMX resistance (40% vs 14%, p <0.0001).

63 duces clinical episodes of malaria; however, TMP-SMX effect on Plasmodium liver stages requires furth

64 nd is likely responsible for the increase in TMP-SMX resistance.

65 n due to toxicity was significantly lower in TMP-SMX (7.3%; 95% confidence interval [CI], 4.7-11.4; I

66 Resistance to at least TMP-SMX and ampicillin was present in 25% of isolate, an

67 We wished to determine if the acquisition of TMP-SMX resistance by CgA occurred before or after the C

68 be carefully weighed against the benefits of TMP-SMX use.

69 and 2 genes and well-characterized cases of TMP-SMX DILI.

70 receiving greater than or equal to 6 days of TMP-SMX at treatment dose (not prophylaxis).

71 alth clinic and analyzed for determinants of TMP-SMX resistance.

72 aimed at determining the optimum duration of TMP-SMX prophylaxis in HIV-infected or HIV-exposed child

73 potential anti-infection immunity effect of TMP-SMX prophylaxis.

74 We compared the efficacy and side-effects of TMP-SMX with TMP-SMX plus doxycycline for the oral phase

75 are commonly prescribed, but the efficacy of TMP-SMX has been questioned.

76 effects of this practice on the emergence of TMP-SMX-resistant bacteria.

77 SMX resistance and knowing the prevalence of TMP-SMX resistance in the local community are important

78 bserved, we recommend the 12-week regimen of TMP-SMX for oral eradication treatment of melioidosis.

79 bserved, we recommend the 12-week regimen of TMP-SMX for oral eradication treatment of melioidosis.

80 esistance to ceftazidime, and limited use of TMP-SMX.

81 incision and drainage alone, clindamycin or TMP-SMX in conjunction with incision and drainage improv

82 ved oral clindamycin 300 mg 4 times daily or TMP-SMX 320 mg/1600 mg twice daily, each for 7 days.

83 patients to receive TMP-SMX plus placebo or TMP-SMX plus doxycycline for 20 weeks (1:1; block size o

84 Oral TMP-SMX is recommended for 12 weeks in Australia and 20

85 than 25 years who were newly dispensed oral TMP-SMX, amoxicillin, or cephalosporins for 3 or more da

86 Twelve weeks of oral TMP-SMX is recommended in Australia, and 20 weeks in Tha

87 Among children prescribed TMP-SMX prophylaxis, there were no significant differenc

88 Among children not prescribed TMP-SMX prophylaxis, 4443 treatments for malaria were gi

89 A rapid increase in the use of prophylactic TMP-SMX in HIV disease was also observed during this tim

90 ce, we randomly assigned patients to receive TMP-SMX plus placebo or TMP-SMX plus doxycycline for 20

91 One participant who received TMP-SMX had a hypersensitivity reaction.

92 ria after DP treatment in children receiving TMP-SMX prophylaxis.

93 However, for children receiving TMP-SMX, associations were strong and evident for all sa

94 In children not receiving TMP-SMX, low piperaquine concentrations were only modest

95 ory failure was higher among those receiving TMP-SMX compared with those receiving amoxicillin or cep

96 hemodynamic changes in the setting of recent TMP-SMX use.

97 rim-sulfamethoxazole (TMP-SMX) and rifampin, TMP-SMX alone, rifampin alone, or tetracycline alone.

98 in 17 of 51 197 patients (0.03%) who started TMP-SMX and in 21 of 197 039 (0.01%) who started cephalo

99 in 15 of 44 801 patients (0.03%) who started TMP-SMX and in 49 of 530 417 (0.01%) who started amoxici

100 l evidence is trimethoprim-sulfamethoxaxole (TMP-SMX) plus doxycycline.

101 ested against trimethoprim-sulfamethoxazole (TMP-SMX) (117/130) were susceptible.

102 omycin (23%), trimethoprim-sulfamethoxazole (TMP-SMX) (9%), and cefuroxime (7%).

103 ation between trimethoprim-sulfamethoxazole (TMP-SMX) and acute respiratory failure in healthy adoles

104 Trimethoprim-sulfamethoxazole (TMP-SMX) and fluoroquinolones were active against 94% an

105 Daily trimethoprim-sulfamethoxazole (TMP-SMX) and insecticide-treated nets remain the main in

106 included oral trimethoprim-sulfamethoxazole (TMP-SMX) and rifampin, TMP-SMX alone, rifampin alone, or

107 indamycin and trimethoprim-sulfamethoxazole (TMP-SMX) are commonly prescribed, but the efficacy of TM

108 lindamycin or trimethoprim-sulfamethoxazole (TMP-SMX) for 10 days.

109 lowed by oral trimethoprim-sulfamethoxazole (TMP-SMX) for 12 to 20 weeks.

110 ors (PIs) and trimethoprim-sulfamethoxazole (TMP-SMX) have known activity against parasites during li

111 Trimethoprim-sulfamethoxazole (TMP-SMX) hypersensitivity reaction, ranging from circula

112 uinolones and trimethoprim-sulfamethoxazole (TMP-SMX) is often used, resistance could reduce its bene

113 Trimethoprim-sulfamethoxazole (TMP-SMX) is widely used for Pneumocystis carinii pneumon

114 Trimethoprim-sulfamethoxazole (TMP-SMX) is widely used in malaria-endemic areas in huma

115 reduced-dose trimethoprim-sulfamethoxazole (TMP-SMX) may be effective in the treatment of Pneumocyst

116 ne (MIN), and trimethoprim-sulfamethoxazole (TMP-SMX) on a set of 205 BCC isolates.

117 nd prescribed trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis.

118 ose receiving trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis.

119 f this trial, trimethoprim-sulfamethoxazole (TMP-SMX) was incorporated for Pneumocystis carinii (PCP)

120 402 (36%) to trimethoprim-sulfamethoxazole (TMP-SMX), 355 (32%) to sulfamethoxazole-sulfisoxazole, 3

121 ansitioned to trimethoprim-sulfamethoxazole (TMP-SMX), an inexpensive alternative treatment.

122 usceptible to trimethoprim-sulfamethoxazole (TMP-SMX), and all isolates were clindamycin susceptible.

123 em, rifampin, trimethoprim-sulfamethoxazole (TMP-SMX), and vancomycin.

124 trofurantoin, trimethoprim-sulfamethoxazole (TMP-SMX), fluoroquinolones (ciprofloxacin, levofloxacin,

125 openem (MEM), trimethoprim-sulfamethoxazole (TMP-SMX), minocycline (MIN), levofloxacin (LVX), ciprofl

126 clindamycin, trimethoprim-sulfamethoxazole (TMP-SMX), or placebo for 10 days.

127 resistance to trimethoprim-sulfamethoxazole (TMP-SMX), the current drug of choice for treatment of ac

128 Additionally, trimethoprim-sulfamethoxazole (TMP-SMX), used for opportunistic infection prophylaxis i

129 Trimethoprim-sulfamethoxazole (TMP-SMX)-associated severe acute respiratory distress sy

130 TI) caused by trimethoprim-sulfamethoxazole (TMP-SMX)-resistant Escherichia coli is increasing and va

131 adiazine, and trimethoprim-sulfamethoxazole [TMP-SMX]) and abstracted data on maternal, pregnancy, an

132 sulfonamides (trimethoprim-sulfamethoxazole [TMP-SMX]), and macrolides.

133 h as Bactrim (trimethoprim-sulfamethoxazole; TMP-SMX) continue to play an important role in treating

134 uld be considered in patients with suspected TMP-SMX respiratory failure.

135 terruption, and 5 patients were still taking TMP-SMX.

136 4% vs 14% no SBPPr, p <0.0001); those taking TMP-SMX had higher TMP-SMX resistance (40% vs 14%, p <0.

137 Despite the known effects that TMP-SMX has in reducing clinical malaria, its impact on

138 nt malaria models, we previously showed that TMP-SMX, at prophylactic doses, can arrest liver stage d

139 ent of malaria parasites and speculated that TMP-SMX prophylaxis during repeated malaria exposures wo

140 Our findings suggest that TMP-SMX is not inferior to TMP-SMX plus doxycycline for

141 The TMP-SMX vs amoxicillin and TMP-SMX vs cephalosporins coh

142 The TMP-SMX vs amoxicillin cohort included 575 218 individua

143 The TMP-SMX vs cephalosporins cohort included 248 236 indivi

144 clindamycin group was similar to that in the TMP-SMX group (221 of 266 participants [83.1%] and 215 o

145 ndamycin group (15 of 221, 6.8%) than in the TMP-SMX group (29 of 215 [13.5%], P=0.03) or the placebo

146 (264 in the clindamycin group and 260 in the TMP-SMX group), including 155 children (29.6%).

147 5% in the clindamycin group and 88.2% in the TMP-SMX group; difference, -1.2 percentage points; 95% C

148 3% in the clindamycin group and 77.7% in the TMP-SMX group; difference, -2.6 percentage points; 95% c

149 n the TMP-SMX plus placebo group than in the TMP-SMX plus doxycycline group (122 [39%] vs 167 [53%]).

150 us placebo group and 21 patients (7%) in the TMP-SMX plus doxycycline group developed culture-confirm

151 16 patients (5%) in the TMP-SMX plus placebo group and 21 patients (7%) in the T

152 verse drug reactions were less common in the TMP-SMX plus placebo group than in the TMP-SMX plus doxy

153 d and randomly assigned 626 patients: 311 to TMP-SMX plus placebo and 315 to TMP-SMX plus doxycycline

154 ents: 311 to TMP-SMX plus placebo and 315 to TMP-SMX plus doxycycline.

155 and palate was higher for infants exposed to TMP-SMX vs beta-lactam antibiotics.

156 Three patients had previous exposure to TMP-SMX and developed symptoms in 1 day or less, while t

157 First trimester exposure to TMP-SMX was associated with increased risk of neural tub

158 ings suggest that TMP-SMX is not inferior to TMP-SMX plus doxycycline for the oral phase of melioidos

159 erial cross-sectional study of resistance to TMP-SMX among all clinical isolates of Staphylococcus au

160 tion of Shigella isolates with resistance to TMP-SMX was 40% among white persons, 58% among Hispanic

161 llege community was found to be resistant to TMP-SMX.

162 when the infecting pathogen is resistant to TMP-SMX.

163 ety of pyrimethamine-containing therapies vs TMP-SMX.

164 ct liver stage Plasmodium parasites, whereas TMP-SMX prevents patent parasitemia.

165 All carriers of HLA-B*14:01 with TMP-SMX DILI possessed HLA-C*08:02, another significant

166 HLA-B*14:01 is associated with TMP-SMX DILI in European Americans, and HLA-B*35:01 may

167 zed clinical characteristics associated with TMP-SMX.

168 n American and African American persons with TMP-SMX DILI were compared with respective population co

169 ons, we currently recommend prophylaxis with TMP-SMX and advise deletion of corticosteroids for patie

170 he efficacy and side-effects of TMP-SMX with TMP-SMX plus doxycycline for the oral phase of melioidos

171 th clindamycin (58 of 265 [21.9%]) than with TMP-SMX (29 of 261 [11.1%]) or placebo (32 of 255 [12.5%

172 Nine patients were treated with TMP-SMX and rifampin.

173 lower clinical cure rates when treated with TMP-SMX for an infection that is resistant to the drug.

174 men with uncomplicated cystitis treated with TMP-SMX when the infecting pathogen is resistant to TMP-

175 e relapsed and was successfully treated with TMP-SMX.

176 d end-organ dysfunction after treatment with TMP-SMX at a large university hospital system during Jan

177 Treatment with TMP-SMX within 2 weeks of the reaction.